Search Results for “ obesity” – Page 8 – media

The “No.1 Chinese hepatitis C drug” is looking for a new engine

Recently, Ascletis announced that its independently developed small molecule GLP-1R agonist ASC30 is undergoing two Phase I clinical trials in the United States for the treatment of obesity with monthly subcutaneous injections and daily oral tablets. With the launch of these two Phase I clinical trials, Ascletis has officially entered the field of weight loss drugs. This is another highlight of the pipeline after Ascletis announced in April this year that it would focus on the development of core non-alcoholic steatohepatitis (NASH) drugs. Urgent need for a new engine Like most biotechs, Ascletis has also been moving forward by trial and error. However, Ascletis is luckier than most biotechs. It has become famous for its first local original hepatitis C drug Ganovo, which not only broke the monopoly of multinational companies such as Gilead, AbbVie, Bristol-Myers Squibb, and Merck in the domestic hepatitis C drug market, ...
- Source: https://news.yaozh.com/archive/44305.html
- 74
- October 1, 2024
Wealth myth” of GLP-1

Recently, the Lasker Award, an important award in the field of biomedicine known as the “vane” of the Nobel Prize, was announced. Among them, the “Clinical Medical Research Award” was awarded to Joel Habener (Massachusetts General Hospital), Lotte Bjerre Knudsen (Novo Nordisk) ) and Svetlana Mojsov (Rockefeller University). The reason for the award is that they discovered and developed GLP-1-based drugs, which revolutionized the treatment of obesity. GLP-1, glucagon-like peptide-1, is a peptide hormone encoded by the human glucagon gene and secreted by intestinal L cells. It can promote the synthesis and secretion of insulin and suppress appetite. Delaying the emptying of gastric contents, etc. Representative products include Novo Nordisk’s semaglutide and Eli Lilly’s tilpotide. It is worth mentioning that the research on GLP-1 has not only received attention from academic awards, but also brought “vast wealth” to companies in the industrial chain due to the huge market demand. The ...
- Source: drugdu
- 94
- September 25, 2024
Novo Nordisk’s new anchor

In the first half of 2024, Novo Nordisk achieved revenue of 133.4 billion Danish kroner, a year-on-year increase of 24%, and its performance continued to grow. The increase in the volume of semaglutide is a key factor in the growth of performance. Ozempic, a semaglutide hypoglycemic injection, achieved revenue of 56.7 billion Danish kroner, Rybelsus, a semaglutide hypoglycemic oral agent, achieved revenue of 10.9 billion Danish kroner, and Wegovy, a semaglutide weight loss injection, achieved revenue of 21 billion Danish kroner. The total sales of semaglutide were 88.7 billion Danish kroner, a year-on-year increase of 43%, accounting for 2/3 of Novo Nordisk’s total revenue. While semaglutide is selling well around the world, Novo Nordisk is also constantly adjusting and optimizing its R&D strategy and business layout. By enriching its product portfolio, it will further strengthen its dominant position in the field of blood sugar and fat reduction. At the same ...
- Source: drugdu
- 58
- September 20, 2024
$1.8 billion! Lilly builds factory and expands GLP-1 production

Disclaimer: Due to limited proficiency, errors are inevitable, or some information may not be timely. Please feel free to leave a message to indicate. This article only provides an introduction to medical and health-related drugs, and does not recommend treatment plans (if applicable); This article does not constitute any investment advice. Lilly said that the company had completed the $800 million Kinsale factory expansion project to increase the production of its obesity and diabetes drugs Mounjaro and Zepbound. At the same time, the pharmaceutical company will also invest $1 billion to build a factory in Limerick to increase the production of biopharmaceutical raw materials, especially Kisunla, a drug approved by the FDA to treat Alzheimer’s disease two months ago. The production of active pharmaceutical ingredients is expected to begin in 2026. Lilly stated that Limerick’s expansion will add tools for artificial intelligence, automated robots, and machine learning to the website. ...
- Source: drugdu
- 76
- September 16, 2024
Increasing Investment in R&D Innovation to Deepen Product Competitive Moats

CSPC Pharmaceutical Group has achieved significant milestones in research and development, securing conditional approval for its self-developed Class 1 new drug, Enlansub, and for the injectable version of Rayzoprazole. The company has also received approval for clinical trials in the U.S. for its antibody-drug conjugate, clinical trial approval for its mRNA vaccine against respiratory syncytial virus, and clinical trial approval for the first CAR-T cell injection based on mRNA-LNP technology. As an innovation-driven enterprise and a key player in the national industrial chain, CSPC continues to enhance its R&D investments, elevate its international influence, and fortify its product competitive edge. This year, various in-development drugs have reached key progress points, with some approved for market launch or clinical trials both domestically and internationally. Currently, CSPC is conducting over 130 innovative drug projects, with more than 50 new drugs expected to be launched in the next five years. Comprehensive Market Coverage ...
- Source: drugdu
- 75
- September 14, 2024
Nature Journal | Revealing the Cell Membrane Protein Interactions of Endogenous GLP-1 Receptors!

As a drug therapy target for obesity and type 2 diabetes, glucagon like peptide-1 receptor (GLP-1R) is widely distributed in many tissues and has cell type specific physiological functions. For example, GLP-1R mainly regulates insulin secretion and cell proliferation in pancreatic islets, and has functions such as appetite suppression, neuroprotection, and anti-inflammatory in the brain. Considering that the maturation, localization, activation, and endocytosis of receptors are all influenced by protein interactions, exploring the interactions between receptors and other membrane proteins on the cell surface can provide important clues for the study of the regulatory mechanism of GLP-1R. However, due to the low expression levels and transient and weak interactions of most membrane receptors, the study of the interaction between endogenous GLP-1R and cell membrane proteins requires the development of new research methods. On September 3, 2024, the iHuman Institute of ShanghaiTech University and the research group led by Shui Wenqing ...
- Source: drugdu
- 57
- September 12, 2024
Up to 1 billion US dollars! An RNA pharmaceutical company has reached a cooperation agreement with Eli Lilly

On September 4, 2024, HAYA Therapeutics, a pioneering biotechnology company that uses precise RNA guidance to regulate genome targeting therapy for chronic diseases, announced the signing of a multi-year cooperation agreement with Eli Lilly. Both parties will utilize HAYA’s advanced RNA guided regulatory genome platform to support preclinical drug discovery for obesity and related metabolic diseases. The partner will identify multiple RNA targets derived from the regulatory genome to treat these chronic diseases. According to the terms of the cooperation agreement, HAYA will receive a down payment, including equity investment, and is eligible to receive up to $1 billion in preclinical, clinical, and commercial milestone payments, as well as royalties for product sales. HAYA’s proprietary regulatory genome discovery platform can identify long non coding RNA (lncRNA) targets specific to tissues, diseases, and cells, and develop treatment methods targeting RNA, which may have better efficacy and lower toxicity compared to current ...
- Source: drugdu
- 60
- September 9, 2024
JCI | Zhu Yingjie’s team from Shenzhen Advanced Institute reveals a new central target of GLP-1R agonist, a “weight loss drug”

Obesity, as one of the top ten chronic diseases worldwide, has a research history of over a century in the field of weight loss drugs. After 2014, glucagon like peptide-1 (GLP-1) receptor agonists emerged as a new force, far surpassing other weight loss drugs in terms of efficacy and safety, and also driving the development and marketing of weight loss drugs. GLP-1, as an intestinal insulinotropic hormone, is generated by the post-translational cleavage of pre glucagon encoded by the pre glucagon gene (GCG). It is mainly secreted by intestinal L cells and a portion of neurons in the solitary tract nucleus (NTS) of the brainstem. The action of GLP-1 is mediated by the GLP-1 receptor (GLP-1 R) and is widely distributed in the peripheral and central nervous systems. Liraglutide is a short acting GLP-1 receptor agonist that acts on the central nervous system to reduce appetite and slow gastric emptying. ...
- Source: drugdu
- 100
- September 5, 2024
The Lancet reports that semaglutide has the potential to be used in heart failure patients

Recently, The Lancet published a new centralized, participant level analysis of heart failure patients with mild reduced ejection fraction or preserved ejection fraction (HFpEF) from four randomized placebo-controlled trials (2.4 mg for SELECT, STEP-HFpEF, STEP-HFpEF DM; 1.0 mg/d). picture According to analysis, semaglutide reduced the composite risk of cardiovascular (CV) death or worsening heart failure (HF) events by 31%, with incidence rates of 5.4% in the semaglutide group and 7.5% in the placebo group (HR 0.69; 95% CI 0.53-0.89; P=0.0045). semaglutide also reduced the risk of HF worsening by 41% (2.8% vs. placebo 4.7%; HR 0.59 (95% CI 0.41-0.82), p=0.0019). Simeglutide had no significant effect on the incidence of CV mortality (3.1% in the Simeglutide group and 3.7% in the placebo group). Hr 0.82 (95% CI 0.57-1.16), p=0.25) The statistical analysis did not adjust for multiplicity, and the hazard ratio should not be used to infer definitive treatment efficacy. In ...
- Source: drugdu
- 72
- September 5, 2024
The Low Point of Performance Due to Centralized Procurement Has Passed, and Tonghua Dongbao Ushered in a Stable Development Period

On the evening of August 30, Tonghua Dongbao (600867.SH) released its 2024 semi-annual report, during the report period, the company achieved operating income of about 740 million yuan, a year-on-year decrease of 45.84%; net profit attributable to shareholders of listed companies of about -230 million yuan; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of about -0.13 billion yuan. Industry analysts believe that the reason why Tonghua Dongbao fell into a loss, stemming from the biggest cyclical factors – insulin special centralized procurement. Similar to the first centralized procurement, the results of this year’s renewal have not been reflected in the performance for the time being. The main reason for the company’s first-half performance fluctuations is a one-time dealer to make up the difference, which was also the case in the last centralized procurement, fell to a low point in the second quarter, the ...
- Source: drugdu
- 79
- September 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.